Life sciences companies were popular targets of class action securities lawsuits in 2018.
In the most recent edition of our annual survey, Dechert litigators David H. Kistenbroker, Joni S. Jacobsen and Angela M. Liu examine these trends as well as why life sciences companies have remained attractive targets for class action securities fraud claims. They also offer best practices for life sciences companies to reduce their risk of being targeted.
Please see full publication below for more information.
